Kedrion Biopharma has announced that China’s National Institutes for Food and Drug Control (NIFDC) has approved BPL’s human Albumin product for release to the Chinese market. BPL is part of Kedrion since 2022. As the first ever approval for a BPL product in China, this is a major milestone for our whole company, which from now can ship to the country on a regular basis. China is by far the largest human Albumin market in the world of 627 tons vs global demand of 1,368 tons in 2021 .
“We are delighted to be able to provide this product to patients in China,” said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. “Obtaining this important license and full distribution agreement in China reflects strongly on our current plan for global expansion while highlighting our corporate mission of providing plasma-derived products worldwide, supporting both healthcare professionals and patients every day.”
Zhou Xianfeng, Chairman of Board, Hangzhou Jiansheng Medicine Co. Ltd. said, “We are delighted to have partnered with BPL and Kedrion, which are truly committed to making therapies available in all parts of the world by expanding into important new markets such as China.”
